Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely
Total raised: $3.3M
Investors 5
Date | Name | Website |
- | Cultivatio... | cultivatio... |
- | iSelect Fu... | iselectfun... |
- | Missouri T... | missourite... |
- | Lagomaj Ca... | lagomaj.co... |
- | Argonautic | argonautic... |
Funding Rounds 2
Date | Series | Amount | Investors |
07.04.2015 | Series A | $2M | - |
09.09.2014 | Series A | $1.3M | - |
Mentions in press and media 15
Date | Title | Description | Source |
19.01.2017 | John Talley Turns His Attention to Cancer Therapy | For Euclises, it’s simple. Without the work of John Talley, Ph.D., the world would not have Celebre... | iselectfun... |
19.01.2017 | John Talley Turns His Attention to Cancer Therapy | For Euclises, it’s simple. Without the work of John Talley, Ph.D., the world would not have Celebre... | iselectfun... |
09.12.2015 | Euclises Pharmaceuticals, Inc. Receives Notice of Patent All... | ST. LOUIS–(BUSINESS WIRE)–December 9, 2015– Euclises Pharmaceuticals, Inc., a biopharmaceutical com... | venturebea... |
20.10.2015 | A Q&A session with Euclises’ John Talley | [iSelect] You have the honorable position of being one of the leading medicinal chemists in the worl... | iselectfun... |
20.10.2015 | The New American Entrepreneur – Euclises | Euclises is drug discovery and development company targeting some of the deadliest cancers out there... | iselectfun... |
20.10.2015 | A Q&A session with Euclises’ John Talley | [iSelect] You have the honorable position of being one of the leading medicinal chemists in the worl... | iselectfun... |
07.04.2015 | Euclises Completes Financing Round | ST. LOUIS–(BUSINESS WIRE)–April 7, 2015– Euclises Pharmaceuticals, Inc., a pharmaceutical company d... | venturebea... |
07.04.2015 | Euclises Pharmaceuticals Completes Nearly $2M Series A Fundi... | Euclises Pharmaceuticals, Inc., a a St. Louis-based biotechnology company developing third-generatio... | finsmes.co... |
27.01.2015 | Euclises Announces Appointment of Bobby Sandage as New CEO | Development Experience to Drive Entry of Novel COX-2 Inhibitors into Clinical Trials for Cancer ST.... | venturebea... |
20.01.2015 | BioTech Selection Committee: Bobby Sandage | Spotlight: Selection Committee Member A Brief Background: Bobby W. Sandage, Jr., Ph.D. has 34 year... | iselectfun... |
Show more